NDAINTRAVENOUSPOWDER
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
5/8 — Partial
CEFAZOLIN SODIUM (cefazolin) by R-Pharm US is [see microbiology (12. Approved for bacterial infections, surgical site infection, osteomyelitis and 3 more indications. First approved in 2023.
Drug data last refreshed Yesterday
Mechanism of Action
[see Microbiology (12.4)] .
Indications (6)
Worked on CEFAZOLIN SODIUM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.